MUSC Psychiatry Chair
Update
December 2015

Thomas W. Uhde, MD
Department of Psychiatry and
Behavioral Sciences & Institute of
Psychiatry
Dr. Jennifer Correll is a licensed psychologist in the Division of Bio-Behavioral Medicine in the Department of Psychiatry and Behavioral Sciences. She received a BA in psychology from Columbia College and a PhD in Clinical Psychology with specialization in rural primary care practice from East Tennessee State University after completing her internship at Cherokee Health Systems. Following a two year behavioral medicine fellowship at MUSC she joined the faculty in 2014.

Dr. Correll’s clinical interests include psychological adjustment to chronic health conditions including cancer, end stage organ disease, chronic pain, diabetes, and heart disease. Her clinical effort is divided between the bio-behavioral medicine outpatient clinic at IOP and the behavioral medicine service at Hollings Cancer Center where she directs the Distress Management Program. Dr. Correll is passionate about collaborative care and has spearheaded integrated care teams across a variety of medical settings with a recent focus on piloting an integrated care model within Hollings Cancer Center’s breast oncology program. She works to advocate for collaborative care at a state and national level in her role on the Membership Committee of the Collaborative Family Healthcare Association which is an organization promoting comprehensive and cost-effective models of healthcare delivery that integrates physical and emotional wellbeing. Dr. Correll is actively involved in training and mentorship, currently serving as a clinical supervisor for pre-doctoral clinical psychology interns rotating through Hollings Cancer Center and Behavioral Medicine-IOP rotations along with post-doctoral fellows in Behavioral Medicine.

Dr. Correll’s research is clinically oriented and geared toward overall adjustment to significant health stressors and interprofessional care of patients living with chronic medical conditions. In her spare time you can usually find her running with her dog, riding horses, or boating. She is also an active member of the Junior League of Charleston.
Dr. Jenna McCauley is an Assistant Professor and licensed clinical psychologist in the Addiction Sciences Division of the Department of Psychiatry and Behavioral Sciences. She received her BS in Psychology, MS in Clinical Psychology, and PhD in Clinical Psychology from the University of Georgia in Athens, Georgia. Dr. McCauley completed her pre-doctoral internship at the Charleston Consortium Psychology Internship Program at MUSC, as well as a two-year, National Institutes of Mental Health sponsored research postdoctoral fellowship at the National Crime Victims Research and Treatment Center at the Medical University of South Carolina.

Dr. McCauley’s primary research is focused on the evaluation, dissemination, and implementation of interventions targeting substance abuse, trauma, and high-risk health behaviors. In the past, Dr. McCauley has served as Co-Investigator on a number of e-health development and evaluation projects, as well as clinical trials of traditionally delivered mental health and substance abuse treatment interventions. Dr. McCauley’s current work was recently funded by the National Institute on Drug Abuse (NIDA; K23 award) and is focused on the dissemination and implementation of best practices in risk reduction targeting prescription opioid misuse, abuse, and diversion among healthcare providers. To date, this NIDA K23 project has fostered ongoing collaborations with the South Carolina Prescription Drug Monitoring Program (Department of Health and Environmental Control), the National Dental Practice Based Research Network, and the South Carolina Dental Association toward the integration of risk mitigation strategies into routine dental practice.
Dr. Deborah Deas was named Associate Provost for University Strategic Advancement. Dr. Deas will work directly with the executive leadership of the MUSC enterprise, Imagine MUSC 2020's Strategic Advisory Committee, leadership of MUSC Health, the deans of the colleges, center directors, and the various workgroups that will be formed in the coming months to ensure a coordinated implementation. This appointment is effective July 1, 2016. Congratulations Dr. Deas!
SPRING CYCLE FOR
PROMOTION & TENURE

For anyone who is requesting promotion or tenure effective January 1, 2017, all promotion and tenure requests must be received in the Chairman’s office no later than February 9, 2016, in the form of complete packets accompanied by a letter of recommendation from your Division Director. Packets with checklists, requests for materials, and forms specific for regular and modified faculty have been developed to make the submission process more straightforward. Packets are available on the College of Medicine’s website. Follow this link: http://academicdepartments.musc.edu/com/faculty/apt/musc/index.html. The letter of recommendation from your Division Director must follow appendix 2 in the COM APT guidelines. Division Director letters should include the following paragraphs: introductory, education, research if applicable, scholarly publications, clinical practice if applicable, administration, and other activities and accomplishments. If you have any questions, please contact Kristen Mulholland mulhollk@musc.edu.

CHARLESTON CONSORTIUM
CLINICAL PSYCHOLOGY
INTERNSHIP PROGRAM WINS
PRESTIGIOUS NATIONAL AWAWRD

At its 49th Annual Convention in Chicago, IL, on November 13th, the Association for Behavioral and Cognitive Therapies (ABCT) presented its award for Outstanding Training Program to the MUSC Department of Psychiatry and Behavioral Sciences/Ralph M. Johnson Veterans Administration Medical Center Clinical Psychology Internship Program. The Charleston Consortium Internship Program was established in 1972 and has provided clinical scientist psychology internship training to 580 interns, many of whom have achieved substantial academic and professional success at academic medical centers and universities throughout the nation. Drs. Dean Kilpatrick and Daniel Smith, Co-Directors of the Program, received this award on behalf the many faculty members, interns, program graduates, and staff who have made this training program a success. Former psychology interns now occupy distinguished faculty in leadership positions within the Department of Psychiatry and other parts of the MUSC, and these former graduates have been particularly successful in obtaining extramural grant funding.

In announcing the award, ABCT highlighted several features of the program that influenced their decision to recognize The Charleston Consortium. Specifically, it noted that the program’s training philosophies mirror those of ABCT: clinical practice and clinical science should inform each other and coexist side by side; specialty training should be complemented by generalist training; research and clinical care should benefit and be available to everyone who needs it; and that the future of our profession is best served by training young professionals to flourish in a changing environment. ABCT also highlighted the impact that the Charleston Consortium’s graduates have made in numerous domains of psychological science, clinical practice, and professional training.
Dr. Viktoriya Magid was featured on Live 5 news discussing the new designer drug, Flakka--a drug that causes people to hallucinate, have uncontrollable actions. http://www.live5news.com/story/30542761/live-5-investigates-flakka-in-colleton-county#.VkvueOyA7Nk.email

Dr. Connie Guille received one of the Society of Biological Psychiatry’s 2016 Chair’s Choice Awards. She will attend the SOBP meeting in May 2016.

Dr. Colleen Hanlon received a Research Equipment Enhancement Fund (REEF) from the Office of the Associate Provost for Research Office.

Dr. Gregg Dwyer was the invited speaker for the Charleston County Bar Association and State Bar's Wellness Committee Meeting on 12-24-15, which includes Continuing Legal Education credits for attorneys. My presentation was entitled “Attorneys and Stress: Reactions and Coping.”

Dr. Gregg Dwyer was featured on the MUSC News Center regarding protecting children from predators. www.musc.edu/pr/newscenter/2015/dwyer-gregg-ncmec.html

Drs. Kevin Gray and Lindsay Squeglia were featured on the MUSC News Center www.musc.edu/pr/newscenter/2015/marijuana-misconceptions-weeded-out.html. They discussed weeding out the misconceptions about marijuana.

In the fall, Dr. Dwyer was an invited consultant to the New Jersey Special Treatment Unit of the Division of Mental Health and Addiction Services. He provided on-site review of specified aspects of their treatment program, conducted training of their personnel, and submitted a written report with recommendations.

Congratulations to Kristen Shealy who was named "Best Professional" through the Zonta Foundation. Kristen will be recognized at the Breaking the Silence Award Gala in January 2016. The Zonta Award Gala assists with raising funds and honoring individuals and organizations that make a difference in the lives of domestic violence victims.


Dr. Sheresa Christopher was invited to participate as part of a multi-disciplinary panel for the 32nd Annual Judges and Attorneys Substance Abuse and Ethics Seminar on 12/04/15. The presentation was entitled “NGRI Case Study.”

Dr. Lindsay Squeglia's work was highlighted by George Koob (NIAAA Director) at the annual the American College of Neuropsychopharmacology (ACNP) meeting.
• Doug Roberts-Wolfe (med student), Dr. Will Wright (Fellow), and Thomas Lewis (Chief Resident) won travel awards to the American Academy of Addiction Psychiatry (AAAP).

• Dr. Patrick O’Neil was an invited lecturer at the meeting of the Korean Society for the Study of Obesity.

• Dr. Dwyer was an invited speaker in the annual Continuing Legal Education training program of the South Carolina Office of the Attorney General and presented Attorneys and Stress: Reactions and Healthy Ethical Coping.
CONGRATULATIONS!

Congratulations to the following faculty, residents and staff who were nominated for Golden Apple Awards by medical students for their contributions to medical education.

**Faculty Award Nominees:**
- Callie Lalich, MD
- Christopher Pelic, MD
- Christine Pelic, MD

**House Staff Award Nominees:**
- Mac Abernathy, MD
- Elizabeth Callan, MD
- Joe Cheng, MD
- David Kerek, MD
- Michael Sierra, MD
- A.C. Williams, MD
- Jared Woodward, MD

**Student Body Award Nominee:**
- Melissa Jacob

CONGRATULATIONS!

Congratulations to the following Faculty Excellence Awards block winners:

**Block 1:**
- Kelly Campbell, MD
- David Hoitt, MD
- Rachel Kennedy, MD
- Ashnoo Nanavati, MD
- Christopher Pelic, MD

**Block 2:**
- Kelly Campbell, MD
- Joe Cheng, MD
- Taral Sharma, MD (AnMed Clerkship Director)

**Block 3:**
- Rindy Fernandes, MD
- Chris Fields, MD
- Joe Cheng, MD
Please join us for a

Holiday Luncheon
Tuesday, December 15
11:30am-1:00pm
IOP lobby

Please RSVP by December 7 to mulholk@musc.edu. You MUST RSVP to attend the luncheon. Those attending are encouraged to bring a side dish or a dessert to share. Please email mulholk@musc.edu if you plan to bring a side dish or dessert.

POSTERS AND PRESENTATIONS

<table>
<thead>
<tr>
<th>PI Name</th>
<th>Title</th>
<th>Type</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sarah Book</td>
<td>Retrospective Evaluation of Zubsolv Outcomes-A Longitudinal View (REZOLV)</td>
<td>NEW</td>
</tr>
<tr>
<td>Jeffrey Borckardt</td>
<td>Dose Dependent Effects of tDCS on Post-Operative Pain</td>
<td>YR02 CONT</td>
</tr>
<tr>
<td>Kathleen Brady</td>
<td>The Southern Consortium Node of the Clinical Trials Network (CTN-0064)</td>
<td>SUPP</td>
</tr>
<tr>
<td>Kathleen Brady</td>
<td>Mindfulness-Based Recovery in Veterans with Substance Use Disorders</td>
<td>CONT YR02</td>
</tr>
<tr>
<td>Kathleen Brady</td>
<td>Mindfulness-Based Recovery in Veterans with Substance Use Disorders: IPA for Therese Killeen</td>
<td>CONT</td>
</tr>
<tr>
<td>Kathleen Brady</td>
<td>Mindfulness-Based Recovery in Veterans with Substance Use Disorders: IPA for Sarah Gainey</td>
<td>CONT</td>
</tr>
<tr>
<td>Kathleen Brady</td>
<td>Mindfulness-Based Recovery in Veterans with Substance Use Disorders: IPA for Louise Haynes</td>
<td>CONT</td>
</tr>
<tr>
<td>Kathleen Brady</td>
<td>Mindfulness-Based Recovery in Veterans with Substance Use Disorders: IPA for Nortorius Coleman</td>
<td>CONT</td>
</tr>
<tr>
<td>Kathleen Brady</td>
<td>Mindfulness-Based Recovery in Veterans with Substance Use Disorders: IPA for Margaret Moran-Santa Maria</td>
<td>CONT</td>
</tr>
<tr>
<td>Kathleen Brady</td>
<td>Mindfulness-Based Recovery in Veterans with Substance Use Disorders: IPA for Christine Horne</td>
<td>CONT</td>
</tr>
<tr>
<td>Matthew Carpenter</td>
<td>The Southern Consortium Node of the Clinical Trials Network (CTN-0064)</td>
<td>SUPP</td>
</tr>
<tr>
<td>Mark George</td>
<td>A Randomized, Sham-Controlled Trial Evaluating the Safety and Effectiveness of NeuroStar Transcranial Magnetic Stimulation (TMS) Therapy in Depressed Adolescents</td>
<td>NEW</td>
</tr>
<tr>
<td>Mark George</td>
<td>Preliminary Study Investigating Whether Low Field Magnetic Stimulation (LFMS) Has Antinociceptive Effects in a Laboratory Pain Model</td>
<td>NEW</td>
</tr>
<tr>
<td>Chanita Hughes-Halbert</td>
<td>SmartState Endowed Chair in Prostate Cancer Disparities</td>
<td>CONT</td>
</tr>
<tr>
<td>Dean Kilpatrick</td>
<td>IPA Kilpatrick with US Army Medical Research and Materiel Command (USAMRMC), Congressionally Directed Medical Research Programs (CDMRP)</td>
<td>CONT YR03</td>
</tr>
<tr>
<td>Aimee McRae-Clark</td>
<td>A Phase II, Randomized Trial to Assess the Effectiveness and Safety of the ID-Cap System for Medication Ingestion Monitoring and Enhancing Adherence</td>
<td>NEW</td>
</tr>
<tr>
<td>Patrick O'Neil</td>
<td>Investigation of Safety and Efficacy of Once-daily Semaglutide in Obese Subjects Without Diabetes Mellitus</td>
<td>CHG</td>
</tr>
<tr>
<td>Daniel Smith</td>
<td>TF-CBTWeb Update</td>
<td>CONT YR04</td>
</tr>
<tr>
<td>Michael Sweat</td>
<td>Bringing South African Men into HIV Counseling and Testing (HCT) and Care</td>
<td>NEW</td>
</tr>
<tr>
<td>Name</td>
<td>Title</td>
<td>Type</td>
</tr>
<tr>
<td>--------------------------</td>
<td>-----------------------------------------------------------------------</td>
<td>---------------------</td>
</tr>
<tr>
<td>Sudie Back</td>
<td>CAP - Doxazosin in the Treatment of Co-Occurring PTSD and Alcohol Use Disorders</td>
<td>New</td>
</tr>
<tr>
<td>Sudie Back</td>
<td>IPA-Nathaniel Baker: CAP - Doxazosin in the Treatment of Co-Occurring PTSD and Alcohol Use Disorders</td>
<td>New</td>
</tr>
<tr>
<td>Sudie Back</td>
<td>IPA for Aisling Hodgins: CAP - Doxazosin in the Treatment of Co-Occurring PTSD and Alcohol Use Disorders</td>
<td>New</td>
</tr>
<tr>
<td>Jean Buckner Craig</td>
<td>Validating Triage for Chemical Mass Casualty Incidents - A First Step</td>
<td>Non-Competing Continuation</td>
</tr>
<tr>
<td>K. Michael Cummings</td>
<td>Models For Tobacco Product Evaluation</td>
<td>Non-Competing Continuation</td>
</tr>
<tr>
<td>Carla Danielson</td>
<td>Comprehensive HIV and Substance Abuse Prevention Strategies for Ethnic Minority Teens and Emerging Adults in the Charleston Tri-County Area: EMPOWER Program Capacity Expansion</td>
<td>New</td>
</tr>
<tr>
<td>Therese Killeen</td>
<td>Mindfulness Meditation for the Treatment of Women with Comorbid PTSD and SUD</td>
<td>New</td>
</tr>
<tr>
<td>Michael Sweat</td>
<td>Community-Based Combination HIV Prevention in Tanzania Women at Heightened Risk</td>
<td>Non-Competing Continuation</td>
</tr>
</tbody>
</table>

Cognitive Processing Therapy (CPT)

Friday, February 26, 2016
Medical University of South Carolina
Gazel Auditorium, Strom Thurmond Building, Room 125
8:30 a.m. - 4:30 p.m.

Many trauma survivors may find that they get “stuck” in their thoughts about the trauma and how it negatively impacts their life, which can inhibit a survivor’s ability to heal from the event. Cognitive Processing Therapy is a 12 session empirically supported treatment aimed at helping survivors process the trauma and challenge “stuck points” that negatively impact how survivors see themselves, others, and the world. By learning more adaptive appraisal, survivors can effectively begin to heal from their experiences.

In this one-day workshop, which is part of our new Therapeutic Techniques & Special Populations Series, clinicians will be provided with an informational overview of Cognitive Processing Therapy.

Discuss how to receive formal training in Cognitive Processing Therapy to be considered a certified “CPT Provider” will be provided.

Presented by:
Rachel E. Levine, Ph.D.
FMH/UICBT Team; MST Service Provider
Ralph H. Johnson VAMC
Assistant Professor of Psychiatry and Behavioral Sciences
Medical University of South Carolina

<table>
<thead>
<tr>
<th>Registration Fees</th>
<th>Early Registration (before 02/09/16)</th>
<th>General Registration (1/12/16 - 2/14/16)</th>
<th>Late Registration (on or after 2/15/16)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Military Providers</td>
<td>$185</td>
<td>$210</td>
<td>$235</td>
</tr>
<tr>
<td>All Other Providers</td>
<td>$290</td>
<td>$320</td>
<td>$350</td>
</tr>
<tr>
<td>Students &amp; Trainees</td>
<td>$50</td>
<td>$75</td>
<td>$100</td>
</tr>
</tbody>
</table>

To register online or view all our upcoming events visit us at: www.musc.edu/psycbevent
NEW HIRES

New Hires—Institute of Psychiatry:
Meagan Murphy
Pamela McKibben
Stacie Rumph
Brenda Mccarty
Benjamin Boehm
Molly Mackenzie
Jonathan Ward
Sonya Thomas
Jordyn Craig

APT CLARIFICATIONS
GUIDELINES

Over the past several months, a faculty committee led by Dr. Dan Lackland, chair of the College of Medicine APT Committee, has been reviewing the College of Medicine APT guidelines to identify opportunities for clarification as needed. It is important to note that the APT guidelines themselves have not been changed; rather, clarification has been provided in hopes of making the existing guidelines easier to understand by all parties. The faculty committee submitted their recommended clarifications, which were then reviewed and endorsed by department chairs and other leaders at recent Dean’s Advisory Committee meetings. A copy of the clarification document, along with the APT guidelines and other related information, can be found at http://academicdepartments.musc.edu/com/faculty/apt/musc/index.html.
SELECTED PUBLICATIONS


HOLIDAY CELEBRATION 2015

December 15th 2:00 – 3:30pm

10P Auditorium

Special Performances
Carols
Song and Dance
Games
Special Guests
Save the Date
29th Annual Update in Psychiatry: 
Trending Topics in Substance Abuse 
June 2 & 3, 2016 • Charleston

Co-sponsored by the MUSC Addiction Sciences Division, this year's conference features internationally renowned experts in the field of substance abuse sharing their clinical experience and latest research findings.

Held in MUSC's new Bioengineering Auditorium during Charleston's premier cultural event, Spoleto Festival USA, this conference brings together psychiatrists, neurologists, psychologists, counselors and social workers, as well as researchers, other physicians and healthcare professionals, for two days of networking and education.

For Spoleto Festival details, visit www.spoletousa.org. 
For a list of continuing education opportunities, visit us online at www.musc.edu/psycheevents.
Title: Eagle Eye: Validation of computer-based saccade measures as a sensitive, reliable, and freely available biomarker for tracking subtle neurocognitive changes in Parkinson’s disease.
Sponsor: Michael J. Fox Foundation
Contact: Jenna Renfroe, PhD.; renfroe@musc.edu ; 843-792-6096
Description: This study aims to validate a computer-based task to enable clinicians and researchers to measure saccades without the cost and complexity of traditional eye-tracking equipment.

Title: Development and standardization of an iPhone-based application for quantitative measurement of the pupillary light reflex in healthy adults and patients with Parkinson’s disease. (iDilate)
Sponsor: Chairs Departmental Research Foundation
Contact: Jenna Renfroe, PhD; renfroe@musc.edu ; 843-792-6096
Description: Thisaim of this project is to develop and standardize an application that would allow clinicians, researchers, and community-based safety personnel (e.g., police and EMS) to obtain quantitative measurements of the pupillary light reflex, a highly sensitive measure of neurological functioning.

Title: Atomoxetine Treatment for Cognitive Impairment in Parkinson’s Disease (ATM-Cog).
Sponsor: Michael J. Fox Foundation
Contact: Vanessa Hinson, MD, PhD.; hinsonvk@musc.edu ; 843-792-6096
Description: This is a RCT assessing the safety and efficacy of ATM for cognitive impairment in Parkinson’s disease.

Title: Ranger Resilience and Improved Performance on phospholipid bound Omega-3’s (RRIP-3).
Sponsor: Aker Biomarine
Contact: Travis H. Turner, PhD; turnertr@musc.edu ; 843-577-5011 x5192
Description: This is a RCT examining whether supplementation with phospholipid bound omega-3 improves resiliency to psychophysiological distress in a sample of 400 candidates going through Infantry Basic Officer Leadership Course (IBOLC) and subsequent Ranger training at Ft. Benning. In addition to grades from IBOLC and success/failure in Ranger training, a number of neuropsychiatric measures are included as outcome and mediator/moderator variables.

Title: Better Resiliency Among Veterans with Omega-3’s (BRAVO)
Sponsor: Congressionally Directed Medical Research Program.
Contact: Samantha Wise ; wissa@musc.edu ; 843-792-2425
Description: This RCT seeks to determine if dietary supplementation with omega-3 HUFAs reduces the risk for serious suicidal behaviors in an at-risk clinical population. Changes in cognitive processes specific to suicide risk are evaluated, including implicit associations, response inhibition and sustained attention.
ONGOING STUDIES

Title: Positive Psychotherapy to Improve Autonomic Function and Mood in ICD Patients
Contact: Dr. Lily Christon (Project Coordinator); Dr. Eva Serber (PI)
Contact email: pam-icd@musc.edu
Contact phone number: 843-792-0625
Description: This study is a randomized clinical trial of a positive-emotion focused cognitive-behavioral therapy intervention (Quality of Life Therapy) vs. a heart healthy education intervention among patients with implantable cardioverter defibrillators (ICD), with the primary aim of feasibility and acceptability of QOLT in ICD patients. Secondary aims include obtaining effect size estimates of QOLT on frequencies of arrhythmia episodes and ICD-delivered therapies, parasympathetic activity and regulation, and QOL and psychosocial constructs. Recruitment: patients of MUSC Cardiology

Title: TMS for nicotine addiction
Contact: Scott Henderson or Xingbao Li
Contact email: henderjs@musc.edu or lixi@musc.edu
Contact phone: 843-792-5560 or 843-792-5729
Description: This is a double blind randomized controlled smoking cessation research study sponsored by the National Institute of Drug Abuse. This study is designed to ascertain whether repetitive transcranial magnetic stimulation (rTMS) can affect things that may prompt you to want to smoke and the consumption of cigarettes over a 3-month period. After assessment and inclusion into the study, participants will be randomized to receive a 10-time active rTMS or placebo-like rTMS. Participants must be (1) current cigarette smokers; (2) between 18-60 years old; (3) able to commit approximately 13 hours of time to the study; and (4) have no metal in their body. Compensation will be provided.

Title: Integrative Risk Reduction and Treatment for PTSD and Teen Substance Use Problems
Contact: Liz McGuan, mcguan@musc.edu, 843-792-8361
Description: This program involves a randomized controlled trial (RCT) with subjects ages 13-18 years who have experienced interpersonal violence (physical or sexual abuse/assault, exposure to domestic violence, witness community violence). Subjects are randomized to either receive Risk Reduction through Family Therapy (RRFT) or Treatment As Usual (TAU). Youth will be recruited from local child advocacy centers and the interventions are psychosocial in nature. Follow-up assessments will be conducted at multiple time points through 18-month post entry.

Title: Investigation of safety and efficacy of once-daily semaglutide in obese subjects without diabetes mellitus
Contact: Suzanne Kuker, kuker@musc.edu, 792-5427
Description: This study seeks to determine whether semaglutide, will help non-diabetic people who are obese to lose weight over one year. Participants will be randomly assigned to receive 1 of 5 doses of semaglutide, liraglutide or an inactive placebo and will be enrolled in the study for 59 weeks. The primary measure will be weight change and other measures will include health factors related to obesity such as blood sugar control, blood pressure, and cholesterol. The safety of the drug for weight loss will also be studied.
ONGOING STUDIES

Title: Group Motivational Interviewing (GMI) for Homeless Veterans in VA Services
Contact: Kayla Lamb, Kayla.Lamb@va.gov, 843-577-5011 ext: 5310
Description: We are seeking Veterans who are homeless or in the VA Homeless Program to voluntarily enroll in a VA research study comparing two types of treatment for Veterans who have an alcohol misuse problem. Eligible participants will attend one of two groups: a motivational enhancement group therapy, called ‘The Self-Change Program’, designed to enhance motivation to make a healthier change around using substances by exploring personal goals, values, and strengths for making a change, or a Like Skills Educational Group therapy for improving quality of life and enhancing home stability. The study will recruit participants from within three locations: the Charleston VA Medical Center, the Myrtle Beach Community Based Outpatient Clinic (CBOC), and the Savannah, GA CBOC. Compensation will be provided to qualified participants.

Title: A Randomized, Double-blind, Multicenter, Placebo-controlled, Parallel-group, Efficacy and Safety Study of 2 Doses of Dasotraline in Adults with Attention Deficit Hyperactivity Disorder (ADHD)
Contact: Amanda Wagner, wagne@musc.edu, 843-792-0484
Description: This is a randomized, placebo-controlled, double-blind clinical trial (Phase III) evaluating the safety and efficacy of an investigational medication called Dasotraline in adults with Attention Deficit Hyperactivity Disorder. The study requires weekly visits for 12 weeks, and daily medication compliance.

Title: Smart Capsule for Automatic Adherence Monitoring
Contact: Elizabeth Jones, jonesel@musc.edu, 843-792-5819
Description: The purpose of this study is to determine the acceptability, tolerability, and efficacy of capsules with built-in, ingestible sensors that allow researchers to tell whether or not a patient took them as prescribed. This study is recruiting healthy volunteers.

Title: Effects of transcranial Direct Current Stimulation and Brief Cognitive Intervention on Pain Tolerance.
Contact: Brittan Carter, cartebri@musc.edu, (843) 792-3659
Description: The Departments of Psychiatry and Anesthesiology at MUSC are accepting volunteers for a clinical research study to investigate pain tolerance. The purpose of this study is to determine whether a new medical technology, called Transcranial Direct Current Stimulation (tDCS) can temporarily alter pain tolerance level. tDCS is a minimally-invasive technique (i.e., it does not involve any surgical procedures, additional medication or sedation, or needles) that uses a very small amount of electricity to temporarily stimulate specific brain areas in awake people. The electrical current passes through the skin, scalp, hair, and skull and can temporarily increase or decrease activity in areas of the brain that are thought to be involved with pain perception. Interested participants will be screened on the telephone and then have one appointment lasting approximately 1 hour. Participants must be between the ages of 18 and 75. Participation is confidential, and compensation is available.
ONGOING STUDIES

Title: The Effects of Cognitive Behavioral Therapy and Transcranial Direct Current Stimulation (tDCS) on Fibromyalgia Patients
Contact: Brittan Carter, cartebri@musc.edu, (843) 792-3659
Description: The purpose of this study is to determine whether a new medical technology, called Transcranial Direct Current Stimulation (tDCS), can help reduce fibromyalgia and reduce the need for pain medication when applied in combination with cognitive behavioral therapy (“talk therapy”). tDCS is a minimally-invasive technique (i.e., it does not involve any surgical procedures, additional medication or sedation, or needles) that uses a very small amount of electricity to temporarily stimulate specific brain areas in awake people. The electrical current passes through the skin, scalp, hair, and skull and can temporarily increase or decrease activity in areas of the brain that are thought to be involved with pain reduction. Some preliminary studies suggest that tDCS may be effective in reducing fibromyalgia and altering pain perception in both healthy adults and in patients with various types of pain conditions. Participants must be between the ages of 21 and 85. Participation is confidential, and compensation is available.

Title: Preliminary Study Investigating Whether Low Field Magnetic Stimulation (LFMS) Has Antinociceptive Effects In A Laboratory Pain Model
Contact: Brittan Carter, cartebri@musc.edu, (843) 792-3659
Description: The purpose of this study is to determine whether a new form of non-invasive brain stimulation, called low field magnetic stimulation (LFMS), can relieve pain. LFMS is like another form of brain stimulation called transcranial magnetic stimulation (TMS). This study consists of a 30 minute screening visit and two 90-minute experimental trials separated by approximately one week. Participation is confidential, and compensation is available.

Title: The Effects of Cognitive Behavioral Therapy and Transcranial Direct Current Stimulation (tDCS) on Chronic Lower Back Pain
Contact: veteranpainsc@gmail.com, 843-779-2493
Description: The purpose of this study is to determine whether a new medical technology, called Transcranial Direct Current Stimulation (tDCS), can help reduce chronic lower back pain and reduce the need for pain medication when applied in combination with cognitive behavioral therapy (“talk therapy”). tDCS is a minimally-invasive technique (i.e., it does not involve any surgical procedures, additional medication or sedation, or needles) that uses a very small amount of electricity to temporarily stimulate specific brain areas in awake people. The electrical current passes through the skin, scalp, hair, and skull and can temporarily increase or decrease activity in areas of the brain that are thought to be involved with pain reduction.
• COMPENSATION PROVIDED
• ALL INFORMATION IS CONFIDENTIAL
PARTICIPANTS MUST:
• Be between the ages of 18 - 70
• Suffer from chronic pain
• Be a United States Veteran
• Take a prescription pain medication
Title: rTMS for Adolescent Depression -- upcoming in the next couple weeks
Contact: Annabel Franz, franza@musc.edu, 843-876-5141
Description: We are investigating the safety and efficacy of repetitive TMS as a treatment for adolescent depression for those aged 12-21 years old. We are seeking adolescents of this age range who have not received sufficient benefit from at least one antidepressant medication trial. TMS is currently FDA approved for treating adult depression.

Title: rTMS for Bipolar Depression - current
Contact: Annabel Franz, franza@musc.edu, 843-876-5141
Description: We are investigating repetitive TMS as a treatment for bipolar depression in conjunction with mood stabilizers in adults aged 22-68 years old. We are seeking treatment refractory patients with bipolar disorder. TMS is currently FDA approved for treating adult depression.

Title: rTMS for Reducing Marijuana Craving and Risky Behaviors in Non-Treatment Seeking Heavy Marijuana Smokers - current
Contact: Annabel Franz, franza@musc.edu, 843-876-5141
Description: A pilot trial investigating how TMS to the left dorso-lateral pre-frontal cortex can reduce marijuana craving and impulsive decisions in adults 18-60.

Title: Enhancing Disrupted Reconsolidation: Impact on Cocaine Craving, Reactivity & Use
Contact: Amanda Smith, smitham@musc.edu, 792-6984
Description: The purpose of this double-blind, placebo-controlled study is to examine whether beta-adrenergic antagonist propranolol can attenuate cocaine-associated memories and thereby reduce cocaine craving, cue reactivity, and use in cocaine dependent participants. Participants will receive either placebo, 40mg, or 80mg of propranolol after each of two laboratory sessions of cocaine cue exposure. Participants will be evaluated on cocaine craving, physiological reactivity to cocaine cues, and cocaine use in follow-up sessions for 6 weeks.

Title: Traumatic Exposure and Competency to Stand Trial: Describing Juvenile Offender Characteristics.
Contact: Sheresa Christopher, chrisshe@musc.edu, 792-1461
Description: Exposure to traumatic events is associated with trauma sequelae which has been studied and observed in samples of justice-involved youth. Within this population, a small subset of youth is referred for evaluation of their competency to stand trial due to concerns they may be lacking a factual and rational understanding of the proceedings against them and the ability to assist their attorney in their defense. Despite the high prevalence of trauma exposure and the similarity of deficits observed, little is known about trauma exposure in youth thought to exhibit deficits in those abilities typically associated with competency to stand trial. The current study aims to describe the differences in characteristics between juveniles who are opined competent to stand trial and those who are not. A particular emphasis is placed on the presence and type of past trauma exposure in relation to the nature of the criminal offenses given the high prevalence of trauma in this population.
ONGOING STUDIES

Title: Comparison of Pre-Trial Competency to Stand Trial Defendants’ Characteristics on Outcome of Feigning Measures: A Preliminary Study of Local Norms
Contact: Jennifer Steadham, steadhaj@musc.edu, 876-2140
Description: Deliberate attempts to falsify, fabricate, or grossly exaggerate some aspect of functioning is known as feigning. When feigning is motivated by possibility of external gains (e.g., avoidance of prosecution or lesser punishment), it is known as malingering (Rogers & Shuman, 2005). Malingering has obvious relevance in forensic mental health evaluations, as pre-trial criminal defendants have clear motivations to feign impairment. Feigning strategies can be subdivided into two varieties in criminal forensic contexts: cognitive (i.e., memory or thinking processes) and psychiatric (i.e., symptoms of major mental disorders) impairment. Categorical classifications can be made on the basis of a defendant’s performance on feigning assessment measures, into groups thought to be exaggerating or fabricating impairment (“probable malingers”) or those thought to be responding honestly (“non-malingerers”). In the last decade, direct examinations comparing the characteristics of competency defendants suspected of malingering versus non-malingerers, as classified by feigning measures, have been sparse and most often included as an incidental question in a larger study. For the current study, a sample of competence to stand trial evaluations conducted by MUSC’s Forensic Psychiatry Program will be reviewed. Competency to stand trial reports dated 2011 through August 2015 will be included for review. Evaluation reports will be coded for examinee (e.g., demographic, psychiatric diagnoses, and mental status descriptions) and evaluator characteristics (i.e., specialty field).

Title: CSP556 “rTMS for depressed veterans”
Contact: Matt Schmidt, matthew.schmidt@va.gov, 843-577-5011 ext 5209
Description: This is study for veterans only who have depression. The treatment given is Transcranial Magnetic stimulation. It is a double blind study with a sham (placebo) possibility. There is a screening phase of about 1 week, a treatment phase of 4-6 weeks, and a follow up phase where subjects come in once per month for 5 months. All procedures and assessments done at Ralph Johnson VA. Subject compensation is available up to $400.00.

Title: A Randomized Trial of E-cigarettes: Natural Uptake, Patterns and Impact of Use
Contact: Caitlyn Hood, hooca@musc.edu, 843-876-2291
Description: Electronic cigarettes (e-cigarettes) are the newest and perhaps the most popular non-cigarette products available to smokers. In this study, we will examine how the use of electronic cigarettes affects smoking behavior. Eligible participants will have a 2/3rds chance of receiving a sample of e-cigarettes. Participants must be current, daily cigarette smokers who are 18 years of age or older and interested in trying the e-cigarette.

Title: Oxytocin in Cocaine Dependence
Contact: Lisa Nunn, jenkinli@musc.edu, 792-0476
Description: This study explores the effect of oxytocin on stress response and brain reactivity in individuals with cocaine dependence. Participation consists of a screening visit, three outpatient study sessions, and two brief follow-up visits.
ONGOING STUDIES

Title: Effect of Pregnenolone on Cue-Reactivity in Marijuana-Dependent Individual.
Contact: Lisa Nunn, jenkinli@musc.edu, 792-0476
Description: This study explores the impact of an oral medication, pregnenolone, on drug craving following exposure to marijuana cues. Participation consists of a screening visit and one study session.

Title: Neural Substrates of Emotion: Impact of Cocaine Dependence
Contact: Lisa Nunn, jenkinli@musc.edu, 792-0476
Description: This study explores the effect of oxytocin on brain activity associated with stress in cocaine dependent individuals. Participation consists of a screening visit and one study session.

Title: A Randomized Controlled Trial of Varenicline for Adolescent Smoking Cessation (formal title protocol); Project Quit (nickname)
Contact: Referrals – Team Intake Coordinator; Study Management - Lori Ann Ueberroth, Study Coordinator
Contact email: Referrals – smokingstudy@musc.edu; Study Management – ueberro@musc.edu
Contact phone number: Referrals – 792-4097; Study Management – 792-8220
Description: This is a research study to determine if a medication (varenicline) helps young cigarette smokers quit. Smokers aged 14-21 who participate in the study receive medication or placebo and help with quitting during 12 weekly sessions. Smokers under 18 must have parental consent. There is no cost to participate and compensation is available to those that qualify.

Title: The gender-sex hormone interface with craving & stress-related changes in smoking (formal title protocol); SCOR 3 Nicotine (nickname)
Contact: Referrals – Team Intake Coordinator; Study Management - Lori Ann Ueberroth, Study Coordinator
Contact email: Referrals – smokingstudy@musc.edu; Study Management – ueberro@musc.edu
Contact phone number: Referrals – 792-4097; Study Management – 792-8220
Description: This is a non-treatment study for cigarette smokers ages 18-45, examining gender and reproductive hormone influences on smoking behavior. There is NO requirement that participants be interested in quitting smoking. The study involves 4 clinic visits and compensation is provided for those who qualify.

Title: Gabapentin for Relapse Prevention: Alcohol Withdrawal-Brain GABA/Glutamate Effects
Contact: Konstantin Voronin, voronin@musc.edu, 792-4887
Description: This treatment study is an 16-weeks outpatient clinical trial where subjects will get medication, which might help them to reduce or stop their drinking, or a placebo. This study will recruit and randomize subjects who have expressed an interest in receiving treatment for alcohol dependence. Upon enrollment into this study there will be 11 outpatient visits. Each visit will last about 1-1.5 hours.
ONGOING STUDIES

Title: Impulsivity and Drinking/Craving: Effect of a Dopamine Stabilizer Medication  
Contact: Mark Ghent, ghent@musc.edu, 792-1222  
Description: This non treatment study investigates the effects of a medication in response to alcohol. Individuals (ages 21-40) who complete the study will be paid for their participation. This study does not involve alcohol treatment.

Title: Acceptability and feasibility of the remote monitoring of smoking and relapse in adolescents  
Contact: Taylor York, york@musc.edu, 843-792-0493  
Description: This is a research study that will test a new remote monitoring technology to assess smoking in the natural environment among adolescents and young adults ages 15-25. After assessment and inclusion in the study, participants will be asked to carry two devices (smartphone and a device to assess how much they are smoking) with them for 11 days and answer questions about their smoking, mood, surroundings, etc. Participants will also be asked to make a brief quit attempt lasting for approximately 48 hours. There is no cost to participate and compensation is available to those who qualify. Remote monitoring technology has the potential for fewer clinic visits and a better understanding of smoking among adolescents and young adults.

Title: A novel approach to reduce the use, misuse and abuse of prescription opioids in pregnancy  
Contact: Connie Guille, guille@musc.edu, 843-792-6489  
Description: The aim of this study is to gather feedback from pregnant women using prescription opioids who participate in a Cognitive Behavioral Therapy for Chronic Pain program for the reduction of use, misuse and abuse of prescription opioid medication(s).

Title: Adverse early childhood experience and risk for poor obstetric outcomes in African American women  
Contact: Connie Guille, guille@musc.edu, 843-792-6489  
Description: The aim of this study is to investigate the impact of early childhood adversity on a laboratory stressor and risk for poor obstetric outcomes.

Title: Testing a Promising Treatment for Youth Substance Abuse in a Community Setting  
Contact: Dr. Scott W. Henggeler, henggesw@musc.edu, (843) 876-1800  
Description: The overriding purpose of the proposed randomized trial is to examine the effectiveness of a promising outpatient treatment of adolescent substance abuse delivered in a community-based treatment setting.

Title: Family-Based Treatment for Parental Substance Abuse and Child Maltreatment  
Contact: Dr. Cynthia C. Swenson, swensocc@musc.edu, (843) 876-1800  
Description: The purpose of this randomized controlled trial is to examine the effectiveness of the Building Stronger Families Model versus standard services in Connecticut for physically abuse and/or neglected children whose parents are experiencing severe substance abuse. The study is being implemented through a community based mental health provider. Key outcomes under examination include child behavior, parent behavior, family relations, parent to child violence, reabuse, placement, and parental substance abuse.
ONGOING STUDIES

Title: Psychological First Aid for Victims of Crime  
Contact: Dr. Michael McCart, mccartm@musc.edu, (843) 876-1800  
Description: This study aims to implement and refine research protocols required for a full-scale randomized clinical trial of Psychological First Aid (PFA) for adult victims of crime. PFA is a promising acute intervention designed to reduce the severity and duration of trauma-related distress. Law Enforcement Victim Advocates are being trained to implement PFA with adult crime victims. A pilot trial is comparing PFA to usual services on key mental health outcomes from baseline through 4 months post-baseline.

Title: Synthesizing HIV Behavioral Intervention Effectiveness in Developing Countries  
Contact: Dr. Michael D. Sweat, sweatm@musc.edu, (843) 876-1800  
Description: This is a project in which we are conducting systematic reviews and meta-analysis on evidence of effectiveness of a variety of HIV behavioral interventions in developing countries.

Title: Phase II RCT of Comprehensive Triage HIV Prevention: Tanzania  
Contact: Dr. Michael D. Sweat, sweatm@musc.edu, (843) 876-1800  
Description: The purpose of this study is to conduct a rigorous 3-year Phase II trial of a promising HIV prevention strategy designed to significantly reduce population-level HIV incidence in rural developing country settings with severe generalized HIV epidemics.

Title: Community-Based Combination HIV Prevention in Tanzania Women at Heightened Risk  
Contact: Dr. Michael D. Sweat, sweatm@musc.edu, (843) 876-1800  
Description: This is a two-arm Phase II community randomized controlled trial of a community-based combination HIV prevention intervention among FSWs in Iringa, Tanzania. The combination package examined includes integrated biomedical, behavioral and structural components: The study will establish base rates of key outcomes including HIV incidence and viral load suppression, examine the socio-structural and behavioral pathways of the intervention, assess feasibility, acceptability and safety, and document preliminary effectiveness. (1) mobile HIV testing and risk reduction counseling; (2) service navigation to facilitate access to treatment and retention in care; (3) sensitivity training for HIV clinical care providers; (4) SMS text messages to promote adherence to care and ART; (5) venue-based peer education and condom distribution; and (6) a community drop-in-center to promote cohesion and collective action to reduce stigma and discrimination.

Title: Dyadic-Based Diagnosis, Care & Prevention for Discordant Couples in Tanzania  
Contact: Dr. Michael D. Sweat, sweatm@musc.edu, (843) 876-1800  
Description: The primary goal for the proposed study is to examine the feasibility, safety, and impact on improved care and prevention of novel strategies to identify and engage HIV sero-discordant couples in an integrated prevention and treatment intervention.
ONGOING STUDIES

Title: Bringing South African Men into HIV Counseling and Testing (HCT) and Care
Contact: Dr. Michael D. Sweat, sweatm@musc.edu, (843) 876-1800
Description: The ultimate objective of this research is to provide evidence-based strategies to improve treatment of HIV+ men. Treatment as prevention (TasP) can only work through a three step process: (1) Testing a significant proportion of the population, (2) linkage to care and (3) maintaining in care a significant proportion of HIV+ individuals to the point of viral suppression. The benefits of increased testing, linkage to and maintenance in care for men would be enormous. We propose a study that combines structural and individual level interventions and integrates the results to address our overall objective of maintenance in care to the point of viral suppression.
Aim 1: In a cluster-randomized study, we will investigate whether male-centered mobilization and testing increases the population-level percentage of men who have been tested (within the last 12 months) by more than 10 absolute percentage points. Aim 2: In the individually-randomized design, we will investigate whether POC CD4 testing and individualized case management improves linkage to care (immediately following diagnosis) and viral suppression (12 months later) over POC CD4 testing alone and standard of care. Aim 3: Integrate the results of the two trial components (Aims 1 and 2) to evaluate the joint effect of the interventions on the percentage of HIV+ men who are effectively tested, linked to care and maintained with undetectable VL. The benefits of increased testing, linkage to and maintenance in care for men would be enormous. Men would remain healthier longer, could work and support their families, contribute to rather than deplete household economic resources, raise their children, and they would be less likely to transmit HIV to female partners.

Title: A Pharmacokinetic Comparison of Immediate Release N-Acetylcysteine with Extended Release N-Acetylcysteine in Healthy Adults
Contact: Melissa Michel, michelm@musc.edu, 843-792-1901
Description: Healthy males and females between the ages of 18-50 years are asked to participate in a 12 day outpatient study. The purpose of the study is to determine if a newly developed extended release version of N-Acetylcysteine (NAC) will be acceptable to replace the currently available immediate release formulation of NAC.

Title: A Prospective, Longitudinal, Observational Study to Evaluate Potential Predictors of Relapse in Subjects With Major Depressive Disorder Who Have Responded to Antidepressant Treatment
Contact: Melissa Michel, michelm@musc.edu, 843-792-1901
Description: This study is being done to collect information related to Major Depressive Disorder (MDD). The purpose of this observational study is to identify if answers to self-reported questionnaires about your symptoms and functioning, information about your daily activity and sleep quality, and speech and voice characteristics can be used to predict worsening of MDD in the near future.
Title: A Phase 2, Efficacy, Safety, and Tolerability Study of ALKS 3831 in Schizophrenia with Alcohol Use Disorder.
Contact: Melissa Michel, michelm@musc.edu, 843-792-1901
Description: This study is designed to evaluate the efficacy, safety, and tolerability of ALKS 3831 in schizophrenia with AUD. ALKS 3831 is a combination of olanzapine, an approved antipsychotic treatment for schizophrenia, and samidorphan, a new medication. Potential subjects for this trial are adults with a diagnosis of schizophrenia and alcohol use disorder (AUD) with a recent change in symptoms. The study will test whether olanzapine with samidorphan will aid in lowering alcohol use for subjects at the same time that the combination of the two drugs lessens side effects of olanzapine such as weight gain.

Title: An Open-label, Long-term, Safety and Efficacy Study of Intranasal Esketamine in Treatment-resistant Depression
Contact: Melissa Michel, michelm@musc.edu, 843-792-1901
Description: The main purpose of this study is to assess the long-term safety, tolerability, and effectiveness of esketamine nasal spray plus a newly initiated oral (taken by mouth) antidepressant in patients with treatment-resistant depression. All patients in this study will be treated with esketamine nasal spray plus a new oral anti-depressant. The new oral anti-depressant will be one of the following approved and marketed oral antidepressants: duloxetine (Cymbalta), escitalopram (Lexapro), sertraline (Zoloft), or venlafaxine extended release (Effexor XR).
****Anticipated to start January 2016

Title: Internet Crimes Against Children: Development of a Typology of Offenders for Use in Prevention, Investigations and Treatment
Contact: Dr. Gregg Dwyer, 843-792-1461
Description: This study is based on the collection and analysis of data from Internet Crimes against Children (ICAC) investigated by ICAC Task Forces in 20+ states. The inferential analysis of perpetrator, victim and offense data and content analysis of Internet chats to solicit children serves to inform the mental health, social services, education and legal fields for use in forensic evaluations, treatment planning, criminal investigations, court proceedings and developing public safety strategies for protecting our communities’ youth. Funded by Office of Juvenile Justice and Delinquency Prevention grant # 2010-MC-CX-4003; joint with the University of So. Carolina.

Title: Protecting Children Online: Using Research-Based Algorithms to Prioritize Law Enforcement Internet Investigations
Contact: Dr. Dwyer. 843-792-1461
Description: Using data from ICAC Task Forces across the U.S. to develop empirically-based algorithms to assist law enforcement in prioritizing cases of: child pornography production over possession/distribution; online luring to meet a minor to commit sexual offenses, over luring restricted to online behavior such as sexual chat or exchanging pornographic images; hands-on sexual offense offenders against children over cases of offenders with no known history. Funded by Office of Juvenile Justice and Delinquency Prevention grant # 2011-MC-CX-0002; joint with University of South Carolina, Johns Hopkins University & University of Ottawa.
ONGOING STUDIES

Title: Evaluation of Cue-Induced Brain Activation in Pedophilic Offenders  
Contact: Dr. Gregg Dwyer, 843-792-1461  
Description: This study adapts fMRI neuroimaging to evaluate cue-induced changes in regional brain activity in men with Pedophilic Disorder compared to men without the disorder. It has significant potential for knowledge acquisition. Neuroimaging technology has been used to a limited extent to address the neurobiological underpinnings of deviant sexual behavior, but studies are limited in number as well as in scope. It extends results of previous neuroimaging studies by assessing regional brain activity after cue stimulation with a control group during simultaneous fMRI and penile plethysmography. Funded by a University of Ottawa Medical Research Fund grant; joint with Royal’s Institute of Mental Health Research, University of Ottawa.

Title: Sexually Violent Predators and the Impact of Substance Addiction: A Pilot Study  
Contact: Dr. Gregg Dwyer and Thomas Lewis III, 843-792-1461  
Description: This study evaluates persons committed under the South Carolina Sexually Violent predator (SVP) Act with regard to substance usage, mental health diagnoses, criminal justice, and sex offense data to better understand their relationships. By utilizing SVP Act Multidisciplinary Team review data, information can be obtained comparing persons recommended for commitment to those dismissed from the review process. Given the dearth of empirical study of this population, employing the depth and breadth of data to be examined will enable this pilot study to further the field and public safety efforts at the community level. The Principal Investigator for this study is a General Psychiatry Resident in the DART program with associated funding support.

Title: Enhancing the Identification of Victims of Child Pornography Production and Distribution  
Contacts: Drs. Gregg Dwyer, 843-792-1461  
Description: A unique collaboration with the National Center for Missing and Exploited Children has enabled access to data from a national registry of identified child pornography victims for the first time outside the federal government. The research team has built a database to examine characteristics of identified child pornography victims; how they are identified; relationships between child and perpetrator characteristics; details about the child pornography offenses. This is a multi-national joint project with MUSC CPSPD, Royal’s Institute of Mental Health Research, University of Ottawa, Canada and School of Health in Social Science, University of Edinburgh, Scotland, UK. Funded by a Thorn Foundation grant.